Sarissa Capital Acquisition Corp.

General Information

It is our intention to pursue prospective targets that are focused on health care and biopharma. Sarissa will target businesses with valuations of $500 million to $1 billion that have the potential to be substantially greater over time due to their underlying business characteristics and growth opportunities as a public company. Our focus will be on the health-care industry in the United States and other developed countries.

Alexander Denner, Ph.D., serves as the chairman and CEO of Sarissa Capital Acquisition Corp.

Our sponsor is an affiliate of Sarissa Capital Management LP, a leading health-care and biopharma investment firm. Sarissa was founded in 2013 by Alexander Denner, Ph.D., the firm’s CEO and chief investment officer, following a successful nearly two-decade career as a health-care investor at Morgan Stanley, Icahn Capital and Viking Capital. 


Employees: 0
Founded: 2020
Contact Information
Address 660 Steamboat Rd Greenwich, CT 06830
Phone Number 203-302-2330
Web Address
View Prospectus: Sarissa Capital Acquisition Corp.
Financial Information
Market Cap $218.75mil
Revenues $0 mil (last 12 months)
Net Income $0 mil (last 12 months)
IPO Profile
Symbol SRSAU
Exchange NASDAQ
Shares (millions): 17.5
Price range $10.00 - $10.00
Est. $ Volume $175.0 mil
Manager / Joint Managers Cantor Fitzgerald
Expected To Trade: 10/21/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change